Literature DB >> 17542352

Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets.

S van Os1, M Relleke, P Muniz Piniella.   

Abstract

UNLABELLED: Risperidone is an atypical anti-psychotic, available in various formulations.
OBJECTIVE: The objective of the study was to compare the bioavailability of a generic oral solution of risperidone (Test formulation) and Risperdal tablets (Reference formulation). Both formulations contained 1 mg risperidone per dosing unit.
METHODS: The study was carried out in 32 healthy volunteers under fasting conditions. Risperidone and 9-hydroxyrisperidone concentrations in plasma were determined using HPLC/MS/MS.
RESULTS: The results show that the 90% confidence intervals for the geometric mean ratios of the solution and the tablet formulations were not within the acceptance range of 80 125% for risperidone, whereas the confidence intervals for 9-hydroxyrisperidone were within the acceptance range of 80 - 125%.
CONCLUSION: Bioequivalence between the generic 1 mg/ml risperidone solution and the originator tablet formulation was not proven in this study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542352     DOI: 10.5414/cpp45293

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  5 in total

Review 1.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

Review 2.  Bioequivalence requirements in the European Union: critical discussion.

Authors:  Alfredo García-Arieta; John Gordon
Journal:  AAPS J       Date:  2012-07-24       Impact factor: 4.009

Review 3.  Rational use of generic psychotropic drugs.

Authors:  Maren Carbon; Christoph U Correll
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

4.  Bioavailability of the Common Cold Medicines in Jellies for Oral Administration.

Authors:  Ki Hyun Kim; Minju Jun; Mi-Kyung Lee
Journal:  Pharmaceutics       Date:  2020-11-10       Impact factor: 6.321

5.  Efficacy and safety of brand-risperidone versus similar-risperidone in elderly patients with neuropsychiatric disorders: A retrospective study.

Authors:  Jefferson Cunha Folquitto; Sérgio Barbosa de Barros; Jony Arrais Pinto Junior; Cássio M C Bottino
Journal:  Dement Neuropsychol       Date:  2010 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.